Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zai Lab of Shanghai Plans $150 Million IPO in the US

publication date: Aug 11, 2017
Shanghai's Zai Lab is planning a US IPO that could raise $150 million and value the company at $1 billion, according to knowledgeable sources. The company has already picked Citigroup and JPMorgan Chase as underwriters, though it has not completed a US filing. Zai Lab is led by high-profile Samantha Du, PhD, who previously was responsible for Chi-Med's innovative drug R&D operations. Zai is developing innovative products with an eye toward the China market in oncology, autoimmune and infectious disease areas. The company has in-licensed products from western drug companies, and it started its own drug discovery operations in 2015. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital